|Uganda Ministry of Health - UNAIDS HIV/AIDS Drug Access Initiative - Preliminary Report (UNAIDS, 2000, 14 p.)|
Initiation of therapy
· A total of 905 patients have accessed the UNAID drug access initiative
· Approximately equal numbers of men and women have begun ARV therapy
· Patients presented at an advanced stage of disease; 80% had CD4+ < 200 cells/mm3
· Approximately half of patients were started on 2NRTI and half on HAART; more recently, there has been an increase in the proportion of patients started on HAART
Response to therapy
· Among all patients started on ARVs to date, 58% are alive and remain in care.
· Kaplan-Meier analysis revealed that the probability of surviving and remaining in care was 48% at one year.
· Patients on both 2NRTI and HAART had virologic and immunologic response to therapy, indicating that antiretroviral therapy programs could be successfully implemented in this developing country setting.
· Patients were often started on 2NRTI due to financial constraints. Although those on 2NRTI demonstrated virologic and immunologic improvement, those on HAART had a greater and more sustained response to therapy.
· Resistance to 3TC was common. Markers for antiretroviral drug resistance in Uganda were found to be similar to those of subtype B viruses in the U.S. and Europe, suggesting that similar methods for monitoring resistance can be used in Uganda.